|
[1]
|
Li, C.J. and Li, L. (2015) Tacrolimus in Preventing Transplant Rejection in Chinese Patients—Optimizing Use. Drug Design, Development and Therapy, 9, 473-485. [Google Scholar] [CrossRef]
|
|
[2]
|
Csikany, N., Kiss, D., Deri, M., et al. (2020) Clinical Significance of Personalized Tacrolimus Dosing by Adjusting to Donor CYP3A-Status in Liver Transplant Recipients. British Journal of Clinical Pharmacology, 87, 1790-1800. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Zanger, U.M. and Schwab, M. (2013) Cytochrome P450 Enzymes in Drug Metabolism: Regulation of Gene Expression, Enzyme Activities, and Impact of Genetic Variation. Pharmacology & Therapeutics, 138, 103-141. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Tamasi, V., Vereczkey, L., Falus, A. and Monostory, K. (2003) Some Aspects of Inter-Individual Variations in the Metabolism of Xenobiotics. Inflammation Research, 52, 323-333. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Shah, R.R. and Smith, R.L. (2015) Addressing Phenoconversion: The Achilles’ Heel of Personalized Medicine. British Journal of Clinical Pharmacology, 79, 222-240. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Busi, F. and Cresteil, T. (2005) CYP3A5 mRNA Degradation by Nonsense-Mediated mRNA Decay. Molecular Pharmacology, 68, 808-815. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Provenzani, A., Notarbartolo, M., Labbozzetta, M., et al. (2011) Influence of CYP3A5 and ABCB1 Gene Polymorphisms and Other Factors on Tacrolimus Dosing in Caucasian Liver and Kidney Transplant Patients. International Journal of Molecular Medicine, 28, 1093-1102. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Itohara, K., Yano, I., Tsuzuki, T., et al. (2019) A Minimal Physiologically-Based Pharmacokinetic Model for Tacrolimus in Living-Donor Liver Transplantation: Perspectives Related to Liver Regeneration and the Cytochrome P450 3A5 (CYP3A5) Genotype. CPT: Pharmacometrics & Systems Pharmacology, 8, 587-595. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Emesvari, M., Kobori, L., Paulik, J., Sarvary, E., Belic, A. and Monostory, K. (2012) Estimation of Drug-Metabolizing Capacity by Cytochrome P450 Genotyping and Expression. Journal of Pharmacology and Experimental Therapeutics, 341, 294-305. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Monostory, K., Toth, K., Kiss, A., et al. (2015) Personalizing Initial Calcineurin Inhibitor Dosing by Adjusting to Donor CYP3A-Status in Liver Trans-Plant Patients. British Journal of Clinical Pharmacology, 80, 1429-1437. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Brunet, M., van Gelder, T., Åsberg, A., et al. (2019) Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring, 41, 261-307. [Google Scholar] [CrossRef]
|
|
[12]
|
Hesselink, D.A., Bouamar, R., Elens, L., van Schaik, R.H. and van Gelder, T. (2014) The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation. Clinical Pharmacokinetics, 53, 123-139. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Birdwell, K.A., Decker, B., Barbarino, J.M., et al. (2015) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clinical Pharmacology & Therapeutics, 98, 19-24. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Hjelmesaeth, J., Hartmann, A., Leivestad, T., Holdaas, H., Sagedal, S., Olstad, M. and Jenssen, T. (2006) The Impact of Early-Diagnosed New-Onset Post Transplantation Diabetes Mellitus on Survival and Major Cardiac Events. Kidney International, 69, 588-595. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Yang, L., Maki-Petaja, K., Cheriyan, J., McEniery, C. and Wilkinson, I.B. (2015) The Role of Epoxyeicosatrienoic Acids in the Cardiovascular System. British Journal of Clinical Pharmacology, 80, 28-44. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Zeldin, D.C. (2001) Epoxygenase Pathways of Arachidonic Acid Metabolism. Journal of Biological Chemistry, 276, 36059-36062. [Google Scholar] [CrossRef]
|
|
[17]
|
Hoopes, S.L., Garcia, V., Edin, M.L., Schwartzman, M.L. and Zeldin, D.C. (2015) Vascular Actions of 20-HETE. Prostaglandins & Other Lipid Mediators, 120, 9-16. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
King, L.M., Ma, J., Srettabunjong, S., Graves, J., Bradbury, J.A., Li, L., Spiecker, M., Liao, J.K., Mohrenweiser, H. and Zeldin, D.C. (2002) Cloning of CYP2J2 Gene and Identification of Functional Polymorphisms. Molecular Pharmacology, 61, 840-852. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Tessaro, F.H., Ayala, T.S. and Martins, J.O. (2015) Lipid Mediators Are Critical in Resolving Inflammation: A Review of the Emerging Roles of Eicosanoids in Diabetes Mellitus. BioMed Research International, 2015, Article ID: 568408. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Gervasini, G., Luna, E., García-Cerrada, M., García-Pino, G. and Cubero, J.J. (2016) Risk Factors for Post-Transplant Diabetes Mellitus in Renal Transplant: Role of Genetic Variability in the cyp450-Mediated Arachidonic Acid Metabolism. Molecular and Cellular Endocrinology, 419, 158-164. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Lasker, J.M., Chen, W.B., Wolf, I., Bloswick, B.P., Wilson, P.D. and Powell, P.K. (2000) Formation of 20-Hydroxyeicosatetraenoic Acid, a Vasoactive and Natriuretic Eicosanoid, in Human Kidney. Role of Cyp4F2 and Cyp4A11. Journal of Biological Chemistry, 275, 4118-4126. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Li, X., Zhao, G., Ma, B., Li, R., Hong, J., Liu, S. and Wang, D.W. (2014) 20-Hydroxyeicosatetraenoic Acid Impairs Endothelial Insulin Signaling by Inducing Phosphorylation of the Insulin Receptor Substrate-1 at Ser616. PLoS ONE, 9, e95841. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Eid, S., Maalouf, R., Jaffa, A.A., Nassif, J., Hamdy, A., Rashid, A., Ziyadeh, F.N. and Eid, A.A. (2013) 20-HETE and EETs in Diabetic Nephropathy: A Novel Mechanistic Pathway. PLoS ONE, 8, e70029. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Nair, S., Verma, S. and Thuluvath, P.J. (2002) Pretransplant Renal Function Predicts Survival in Patients Undergoing Orthotopic Liver Transplantation. Hepatology, 35, 1179-1185. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Fernandez, J., Acevedo, J., Prado, V., et al. (2017) Clinical Course and Short-Term Mortality of Cirrhotic Patients with Infections Other than Spontaneous Bacterial Peritonitis. Liver International, 37, 385-395. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Ruiz-del-Arbol, L., Monescillo, A., Arocena, C., et al. (2005) Circulatory Function and Hepatorenal Syndrome in Cirrhosis. Hepatology, 42, 439-447. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Sole, C., Sola, E., Morales-Ruiz, M., et al. (2016) Characterization of Inflammatory Response in Acute-on-Chronic Liver Failure and Relationship with Prognosis. Scientific Reports, 6, Article No. 32341. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Krag, A., Bendtsen, F., Henriksen, J.H., et al. (2010) Low Cardiac Output Predicts Development of Hepatorenal Syndrome and Survival in Patients with Cirrhosis and Ascites. Gut, 59, 105-110. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Schneider, A.W., Kalk, J.F. and Klein, C.P. (1999) Effect of Losartan, an Angiotensin II Receptor Antagonist, on Portal Pressure in Cirrhosis. Hepatology, 29, 334-339. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Yeboah, M.M., Hye Khan, M.A., Chesnik, M.A., et al. (2016) The Epoxyeicosatrienoic Acid Analog PVPA Ameliorates Cyclosporine-Induced Hypertension and Renal Injury in Rats. The American Journal of Physiology—Renal Physiology, 311, F576-F585. [Google Scholar] [CrossRef] [PubMed]
|